# Novartis (NVS) Q2 2026 earnings

Results filed 2026-07-21 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/nvs/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1114448/000111444826000012/0001114448-26-000012-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Novartis returned to sales growth as Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio outgrew Entresto's generic erosion, while Rhapsido and Itvisma launches began building the next growth leg.

Novartis's growth drivers kept expanding. Kisqali grew strongly in early and metastatic breast cancer, Kesimpta has now treated more than 216,000 patients, and Scemblix gained from newly diagnosed CML approvals in 66 markets. Leqvio benefited from China reimbursement listing. Two launches began: Rhapsido, the first approved BTK inhibitor for chronic spontaneous urticaria, and Itvisma, a gene replacement therapy for a broad SMA population. Entresto generics in the US remained the main drag.
Management is steering toward a pure-play innovative medicines company, adding pipeline through acquisitions such as Avidity, Pikavation, Excellergy and the pending Myricx Bio deal, with multiple readouts expected in the second half. The tension is that new launches and acquired assets must replace revenue lost to generics. Lutathera's patent ruling and Entresto and Promacta generics add pressure, and acquisitions have pushed net debt up to USD 39.4 billion.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Net sales | USD 14.4 billion | +3% in USD, +1% at constant currencies |  |
| Operating income | USD 4.8 billion | -2% in USD, -3% at constant currencies |  |
| Net income | USD 3.3 billion | -19% in USD and at constant currencies |  |
| EPS | USD 1.71 | -17% in USD, -18% at constant currencies |  |
| Core EPS | USD 2.41 | 0% in USD, -1% at constant currencies | non-GAAP |
| Core operating income margin | 41.2% | down 1.0 percentage point (0.7 points at constant currencies) | non-GAAP |
| Net cash flows from operating activities | USD 5.9 billion | -12% |  |
| Free cash flow | USD 5.6 billion | -12% | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Kisqali | USD 1 695 million | +44% in USD, +43% at constant currencies |
| Cosentyx | USD 1 824 million | +12% in USD, +10% at constant currencies |
| Kesimpta | USD 1 424 million | +32% in USD and at constant currencies |
| Entresto | USD 1 181 million | -50% in USD, -51% at constant currencies |
| Pluvicto | USD 651 million | +43% in USD and at constant currencies |
| Scemblix | USD 562 million | +89% in USD and at constant currencies |
| Leqvio | USD 480 million | +61% in USD, +59% at constant currencies |
| Rhapsido | USD 64 million |  |

## Key takeaways

1. **Five priority brands drove growth despite generics** Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio all grew by 32% to 89% at constant currency. Together they offset generic losses in Entresto, Promacta and Tasigna, which is why sales returned to growth.
2. **Rhapsido and Itvisma launches are underway** Rhapsido received EC and Japan approval as the first BTK inhibitor for CSU, with USD 64 million in sales supported by payer coverage and a free drug program. Itvisma won EC approval as the only gene replacement therapy for a broad SMA population and is driving Zolgensma Group growth.
3. **Pipeline widened through acquisitions and filings** Novartis completed the Pikavation and Excellergy acquisitions and agreed to buy Myricx Bio, adding ADC assets targeting B7-H3 and HER2. It also submitted del-zota for accelerated approval in DMD.
4. **Kisqali's survival data and exclusivity extend its runway** Six-year NATALEE follow-up showed clinically meaningful overall survival in broad early breast cancer. FDA pediatric exclusivity adds six months to all Orange Book-listed patents.
5. **Lutathera patent loss adds legal risk** A US court ruled against the validity of Lutathera patents expiring in 2039, and Novartis has appealed. No generic maker has final FDA approval, but an at-risk launch before the appeal outcome is possible.

## Questions

**What new products did Novartis launch or get approved this quarter?** Rhapsido won EC and Japan approval for CSU as the first approved BTK inhibitor for the condition, and Itvisma won EC approval as the only gene replacement therapy for a broad SMA population. In July the FDA also granted traditional approval for Fabhalta in IgA nephropathy.
**Which Novartis products are driving growth?** Kisqali, Kesimpta, Scemblix, Pluvicto and Leqvio led growth. Fabhalta and Cosentyx also grew, with Fabhalta expanding in PNH and renal indications and Cosentyx growing in the US in HS and IV.
**How is Novartis dealing with generic competition?** Entresto, Promacta and Tasigna lost sales to generics, with generic competition cutting 14 percentage points from net sales. Novartis is relying on newer brands, launches and Kisqali's extra exclusivity to offset this, and it is litigating generics for Leqvio, Tafinlar + Mekinist and Lutathera.
**What acquisitions did Novartis make or announce?** It completed the Pikavation Therapeutics and Excellergy acquisitions in the quarter, and the Avidity Biosciences deal was funded earlier in the year. In July it agreed to acquire Myricx Bio, expected to close in H2 2026.
**What pipeline events should investors watch next?** Management said it is on track for multiple important readouts in the second half of 2026. Del-zota's accelerated approval filing in DMD is under FDA review, and zigakibart's Phase III BEYOND readout in IgAN is anticipated in H1 2027.

## Slides and investor documents

- [July 2026 (PDF 1.2 MB)](https://www.novartis.com/sites/novartis_com/files/novartis-q2-2026-impact-and-sustainability-update.pdf) (Slide deck)

